The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1480
Drugs for Hypothyroidism
The full article is available to subscribers Subscriber Login   

Primary hypothyroidism is usually the result of Hashimoto's thyroiditis, thyroidectomy, or radioactive iodine therapy. Treatment of hypothyroidism with replacement doses of thyroid hormone is usually lifelong. Levothyroxine is the drug of choice.

LEVOTHYROXINE (LT4) — Pharmacokinetics – In healthy fasting adults, 70-80% of an oral dose of LT4 is absorbed in the jejunum and ileum. LT4 has a half-life of about 7 days, permitting once-daily dosing and maintenance of a steady state despite occasional missed doses. Steady state is reached after about 6 weeks of treatment. Maintaining a steady-state level in the blood ensures sufficient tissue concentrations for peripheral deiodination of biologically inactive T4 into active triiodothyronine (T3).

Dosage – LT4 has a narrow therapeutic index. The usual replacement dose is about 1.6-1.8 mcg/kg/day. Patients with thyroid cancer taking LT4 to suppress ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Immediate Online access to current issue and archives from 1988 to the present
  • Mobile access to our mobile site and free apps for iOS, Android and Kindle
  • FREE online per issue CME/CE
Free trial offer
3 Free Issues of The Medical Letter on Drugs and Therapeutics mailed to your home or office PLUS online access.
Try a Free Trial Subscription
Purchase this article:
Title: Drugs for Hypothyroidism
Article code: 1480b
 Electronic, downloadable article - $25